← All trials
NCT01423500
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2007
- Primary completion
- Sep 1, 2011
- Completion date
- Sep 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 405
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- St. Anna KinderkrebsforschungLead sponsor
- Azienda Ospedaliera San Gerardo di MonzaOverall official - principal investigator
- University of BratislavaOverall official - principal investigator
- Akdeniz UniversityOverall official - principal investigator
- Utrecht UniversityOverall official - principal investigator
- University of CopenhagenOverall official - principal investigator
- St. Anna KinderkrebsforschungStudy chair
- St. Anna KinderkrebsforschungReponsible party - principal investigator
- Istanbul UniversityOverall official - principal investigator
- Poznan UniversityOverall official - principal investigator
- Tel Aviv UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.